secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001649094-25-000073
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025
--------------------------------------------------------------------------------

- Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.
- VAX-24 infant Phase 2 met non-inferiority criteria for 20 of 24 serotypes; robust OPA responses.
- VAX-31 infant Phase 2 advanced to second stage; adult Phase 3 non-inferiority study to start mid-2025.
- New third-generation PCV candidate VAX-XL announced to further expand serotype coverage.
- Dr. Olivier Brandicourt (ex-Sanofi CEO) appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/0001649094-25-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001649094-25-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer